ADMA Biologics, Inc. ADMA
Set alert
At close · Oct 30
After hours · Oct 30, 6:21 PM ET
- YTD
- -37.45%
- 1 year
- -25.28%
- Open
- 11.85
- Prev close
- 11.75
- Mkt cap
- 2.56B
- Vol
- 2.46M
- Avg vol
- 2.68M
- EPS
- 0.70
- P/E
- 16.30
- Div yield
- 0.00%
More statistics
- Low
- 11.37
- High
- 11.90
- Forward P/E
- 12.07
- Beta
- 0.69
- Short ratio
- 5.82
- Inst. own
- 92.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 9.97
- 200-d avg
- 10.99
- 1y target
- 17.00
Key statistics
- Market cap
- 2.55B
- Enterprise value
- 2.70B
- Trailing P/E
- 16.27
- Forward P/E
- 12.07
- PEG ratio
- 0.00
- Price / sales
- 4.98
- Price / book
- 6.29
- EPS (TTM)
- 0.70
- Beta
- 0.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 32.98%
- Revenue (TTM)
- 512.28M
- Revenue growth
- 2.00%
- Free cash flow
- 54.76M
- Total cash
- 136.02M
- Total debt
- 203.84M
- Return on equity
- 41.90%
- Shares outstanding
- 223.98M
- Short % of float
- 10.74%
- 50-day average
- 9.97
- 200-day average
- 10.99
Analyst view
Consensus: none
- Target (low)
- 12.00
- Target (mean)
- 17.00
- Target (high)
- 21.00
- Strong buy1
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.19667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.1967 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.1633 | 0.16 | 0.00 | -2.02% |
| May 6, 2026 | Mar 31, 2026 | 0.1933 | 0.19 | 0.00 | -1.71% |
| Feb 25, 2026 | Dec 31, 2025 | 0.185 | 0.20 | +0.02 | +8.11% |
| Nov 5, 2025 | Sep 30, 2025 | 0.16 | 0.16 | 0.00 | 0.00% |
| Aug 6, 2025 | Jun 30, 2025 | 0.14 | 0.15 | +0.01 | +7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 2026 | Mizuho | main | Outperform | Outperform |
| May 7, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 7, 2026 | Mizuho | main | Outperform | Outperform |
| Apr 21, 2026 | Canaccord Genuity | init | — | Buy |
| Apr 13, 2026 | Mizuho | main | Outperform | Outperform |
| Mar 26, 2026 | Cantor Fitzgerald | down | Overweight | Neutral |
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- admabiologics.com
News
- Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
- Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
- Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
- ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
- Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
- ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
- Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
- ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis
- Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
- ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Your note
Sign in to keep a note on ADMA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELMS STEVEN A | Director | Purchase | Mar 5, 2026 | 0 |
| FINGER ALISON CECILY | Director | Stock Award(Grant) | Feb 8, 2026 | 45,619 |
| GROSSMAN ADAM S | Chief Executive Officer | Sale | Mar 15, 2026 | 3,837,160 |
| GROSSMAN JERROLD B | Director | Purchase | May 26, 2026 | 612,991 |
| GUIHEEN LAWRENCE P | Director | Stock Gift | Mar 16, 2026 | 186,510 |
| KESTENBERG-MESSINA KAITLIN M. | Officer | Sale | Mar 8, 2026 | 466,600 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.12% | 38,355,684 | 436.87M | Jun 29, 2026 |
| State Street Corporation | 7.64% | 17,116,022 | 194.95M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.51% | 10,103,809 | 115.08M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.50% | 10,088,490 | 114.91M | Jun 29, 2026 |
| Rubric Capital Management LP | 4.17% | 9,339,414 | 106.38M | Jun 29, 2026 |
| Capital Research Global Investors | 3.91% | 8,756,374 | 99.74M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 13,332,053 | 151.85M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 4.45% | 9,970,973 | 113.57M | Sep 29, 2026 |
| SmallCap World Fund Inc | 3.81% | 8,524,390 | 97.09M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 7,023,200 | 79.99M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.66% | 5,963,003 | 67.92M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.02% | 4,534,131 | 51.64M | Sep 29, 2026 |